Voyager Therapeutics Announces Incentive Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company focused on advancing neurogenetic medicine, has entered into an employment agreement with a newly hired employee that provides for, among other things, the grant to such employee of a non-qualified stock option and restricted stock units as incentives for such employee to join Voyager. The incentive grants were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option grant became effective on August 28, 2024, and the restricted stock unit grant is expected to become effective on October 1, 2024.

The stock option award provides for the purchase of an aggregate of 40,000 shares of Voyager common stock, and the restricted stock option award represents 20,000 shares of Voyager common stock. The stock option has a term of ten years and an exercise price of $6.49 per share, which is equal to the closing price of Voyager common stock on August 28, 2024, the effective date of the grant. The stock option vests over four years, with 25% of the shares underlying the stock option vesting on the first anniversary of the effective date of the grant and 75% of the shares underlying the stock option vesting in 36 equal monthly installments following the first anniversary of the effective date of the grant. The restricted stock option vests annually in equal installments over three years, beginning on the first anniversary of the effective date of the grant. The vesting of the stock options is contingent upon the employee’s continued employment with Voyager. Each stock option is also subject to the terms and conditions of an award agreement.